Blake Borgeson - 18 Jun 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
18 Jun 2025
Net transactions value
$0
Form type
4
Filing time
23 Jun 2025, 17:23:44 UTC
Previous filing
06 Jan 2025
Next filing
04 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Borgeson Blake Director C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY /s/Jonathan Golightly, attorney-in-fact 23 Jun 2025 0001856094

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +22,016 +0.31% $0.000000 7,089,863 18 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Award $0 +44,031 $0.000000 44,031 18 Jun 2025 Class A Common Stock 44,031 $5.11 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
F2 The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.